Matthew G. Mei, MD
Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation (ASCT) as treatment for mantle cell lymphoma (MCL) had a survival advantage, according to results from a retrospective single-center study.
The 5-year cumulative incidence of relapse was 41% (95% CI, 34-48), with a continuous pattern of relapse events occurring at a median of 2.1 years after ASCT. A total of 83 relapses occurred at a median of 2.1 years posttransplant. Fourteen of 83 patients who relapsed subsequently underwent allogeneic transplant. Secondary malignancies occurred in 14 patients (7%), of which 5 were therapy-related myelodysplastic syndrome or acute myelogenous leukemia (3%). Nonrelapse mortality, defined as any death without a prior relapse, occurred in 16 patients (8%), and was a result of a secondary malignancy in 10 patients (5%).
Mei MG, Cao TM, Song JY, et a. Long-term results of high-dose therapy and autologous stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab. Biol Blood Marrow Transplant [published online ahead of print July 18, 2017]. doi:10.1016/j.bbmt.2017.07.006.
... to read the full story